William Blair Comments on Pyxis Oncology FY2027 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Research analysts at William Blair issued their FY2027 EPS estimates for Pyxis Oncology in a report released on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the company will earn ($1.27) per share for the year. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 target price on shares of Pyxis Oncology in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Pyxis Oncology in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.20.

Pyxis Oncology Trading Up 0.9 %

Shares of PYXS opened at $1.07 on Thursday. Pyxis Oncology has a twelve month low of $0.99 and a twelve month high of $6.18. The company has a market cap of $63.63 million, a P/E ratio of -1.04 and a beta of 1.11. The company’s fifty day simple moving average is $1.34 and its 200-day simple moving average is $2.39.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.01.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC bought a new position in shares of Pyxis Oncology in the third quarter worth about $55,000. ProShare Advisors LLC bought a new position in Pyxis Oncology during the 4th quarter worth about $26,000. MetLife Investment Management LLC grew its holdings in Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after acquiring an additional 5,484 shares in the last quarter. Ameriprise Financial Inc. bought a new position in Pyxis Oncology during the 4th quarter worth about $35,000. Finally, Caption Management LLC bought a new position in Pyxis Oncology during the 4th quarter worth about $35,000. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.